Core outcomes in gestational diabetes for treatment trials: The Gestational Metabolic Group treatment set
| Autor: | Bashir, M., Syed, A., Furuya-Kanamori, L., Musa, O.A.H., Mohamed, A.M., Skarulis, M., Thalib, L., Konje, J.C., Abou-Samra, A.-B., Doi, S.A.R. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
insulin
premature labor hypertension hyperbilirubinemia education prevalence venous thromboembolism Article preeclampsia systematic review consultation controlled study Apgar score human gestational age hemoglobin A1c outcome assessment Embase pregnancy outcome non insulin dependent diabetes mellitus Cochrane Library Medline hydramnios maternal hypertension chorioamnionitis group therapy Delphi study maternal obesity fetus female spontaneous abortion pregnancy diabetes mellitus risk factor gestational weight gain glycemic control metabolic regulation triacylglycerol vaginal delivery hospitalization meta analysis |
| Popis: | Aims With the rising number of outcomes being reported following gestational diabetes (GDM), the outcomes in existing studies vary widely making it challenging to compare and contrast the effectiveness of different interventions for GDM. The purpose of this study was to develop a core outcome and measurement set (COS) for GDM treatment trials. Materials & Methods A Delphi study with structured consultation with stakeholders and discussion within a specialist Gestational Metabolic Group (GEM) were combined with a comprehensive systematic search across different databases (PubMed, Cochrane Library, and Embase). Several Delphi rounds over 2 years were conducted culminating in this report. Results The process resulted in a targeted set of outcomes constituting a “GEM treatment set” aligned with expert opinion. The final COS also included a measurement set for the 11 important clinical outcomes from three major domains: maternal metabolic, fetal, and pregnancy related. Conclusions Based on the results of this study, it is recommended that future clinical trials on GDM report outcomes uniformly keeping to the recommended COS outcomes. Members of the GEM Group who did not qualify for authorship but who contributed to the QMI meetings include: Maha Abdulla H I Al?Asmakh, PhD, Department of Biomedical Sciences, Qatar University. Stephen Atkin, Professor of Medicine; Weill Cornell Medicine?Qatar; Senior Consultant in Endocrinology, Hamad Medical Corporation, Doha, Qatar. Ilham Bettahi, PhD, Qatar Metabolic Institute, Hamad Medical Corporation, Doha, Qatar. Odette Chagoury, PhD, Associate Director Clinical Research at Weill Cornell Medicine, Doha, Qatar. Tarik El Hadd, MD, Department of Endocrinology, Qatar Metabolic Institute, Hamad Medical Corporation (Hamad Teaching Hospital), Doha, Qatar. Ibrahim M. Ibrahim, MD, Endocrine Department, Sidra Medicine, Doha, Qatar. Gianfranco Pintus, PhD, College of Health Sciences, Qatar University, Doha, Qatar. Manjunath Ramanjaneya, BPharm, Qatar Metabolic Institute, Hamad Medical Corporation, Doha, Qatar. Hiba Mahmoud Hassan Satti, MD, Department of Obstetrics and Gynecology, Hamad Medical Corporation, Doha, Qatar. Hessa Ibrahim Shahbic, MD, Assistant Director of Women's Health Clinical Affairs Department, Primary Health Care Corporation, Doha, Qatar. Fatin Taha, MD, Department of Obstetrics and Gynecology, Hamad Medical Corporation, Doha, Qatar. Shahrad Taheri, BSc, MSc, MBBS, PhD, FRCP; Professor of Medicine; Weill Cornell Medicine?Qatar Senior Consultant in Endocrinology, Hamad Medical Corporation, Doha, Qatar. This study was made possible by program grant NPRP 10?0129?170274 from Qatar National Research Fund (a member of Qatar Foundation) to Suhail A. Doi. The findings herein reflect the work and are solely the responsibility of the authors. Open Access funding provided by the Qatar National Library. Scopus |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|